Nasdaq: IMMX/Biotechnology
Immix Biopharma, Inc.
Los Angeles, CA, United States
Company overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.